Home > 2008/2009 Goals


Corporate Responsibility Strategy

Integrate corporate responsibility into Pfizer's core business processes
2009 Goal Metric More Information
Increase Board-level oversight of the corporate responsibility function Provide biannual corporate responsibility updates to the Corporate Governance Committee of Pfizer's Board of Directors on progress on goals and corporate responsibility issues Corporate Responsibility Governance
Engage colleagues in all Pfizer geographies and business units in corporate responsibility Established a Global Corporate Responsibility Colleague Network to link Pfizer colleagues around the world who have corporate responsibility-related roles Corporate Responsibility Governance
Establish approach for regular feedback on Pfizer's corporate responsibility reporting and performance Hold an annual multistakeholder forum focused on feedback on the 2008/09 Corporate Responsibility Report Corporate Responsibility Governance

Facilitate responsible transitions during the economic recession
2009 Goal Metric More Information
Provide laid-off Pfizer employees with resources to find new employment, careers, or other opportunities Each laid-off Pfizer employee to use at least one of the Pfizer resources (including cash, outplacement and retraining allowances) during their transition Colleagues & Community
Enhance internal clarity about changes at Pfizer associated with the proposed acquisition of Wyeth Implement communications strategies globally to help employees stay aware of impending changes and ease adjustments Chairman‘s Letter

Access to Medicines

Improve public health around the world
2009 Goal Metric More Information
Explore strategies that improve health care through new, nontraditional business models that are commercially viable, scalable and sustainable Develop Global Access Strategy to launch pilot programs and innovative partnerships Access to Medicines
Broaden access to medicines and strengthen health care delivery for underserved people around the world Execute on Pfizer's global health programs and publicly report progress. Access to Medicines

Patient Safety

Develop and implement a program to protect the integrity of Pfizer medicines
2009 Goal Metric More Information
Identify and disrupt major manufacturers of counterfeit Pfizer products Develop evidence base upon which authorities can take successful enforcement actions including raids, seizures, arrests and filing of criminal charges Patient Safety
Develop effective partnerships with enforcement and regulatory authorities around the world Enlist support of key officials in anti-counterfeiting efforts through Memoranda of Understanding Patient Safety
Raise awareness of the risks that counterfeit medicines pose to patients Provide fact-based support for Pfizer's policy initiatives with respect to anti-counterfeiting activities Patient Safety

Research & Development

Improve patient health worldwide by developing promising new medicines to treat the world's most serious diseases
2009 Goal Metric More Information
Continue to advance our development pipeline from Phase I through registration, especially in the high priority disease areas Deliver 15ýýý20 Phase III starts in 2008-2009; 24ýýý28 programs in Phase III by end of 2009; 15ýýý20 regulatory submissions from 2010 to 2012 Research & Development
Use the new Business Unit (BU) model to ensure that these efforts remain responsive to the changing needs of patients worldwide Handoff research projects from R&D to Business Units at proof of concept stage. Research Units and Technology Units led by Chief Scientific Officers, supported by strong Partner Lines, with full access to large- and small-molecule drug design platforms Research & Development
Ensure that our R&D efforts remain aligned with our goal to expand research in neglected diseases Continue our public-private partnerships in the development of new treatments for malaria (WHO-TDR), our Zithromax/Chloroquine clinical trials, and Eurartesimýý; development of maraviroc as a microbiocide for HIV; and the joint venture with GlaxoSmithKline on new HIV/AIDS treatments Research & Development
Continue to invest in new technologies that will allow better utilization of our medicines by physicians and patients Investment in development of biomarkers and diagnostic tools that allow better patient and physician utilization of our therapies Research & Development
Expand our commitment to maintaining the highest ethical standards and transparency in our conduct of human clinical trials worldwide Achieved new accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the protection of human subjects taking part in early-stage clinical trials; maintain our leadership in publicly posting clinical trial summary results of all of our clinical trials Research & Development

Environment, Health & Safety

Reduce our impact on the physical environment
2009 Goal Metric More Information
Continue to reduce our GHG emissions Meet our second generation goal to reduce our GHG emissions by 20 percent on an absolute basis between 2008 and 2012 Environment, Health and Safety
Develop a more strategic approach to environmental sustainability as part of Corporate Responsibility platform Endorsement of the Environmental Sustainability Strategy by Pfizer senior leadership Environment, Health and Safety

Public Policy

Support U.S. health care system reform
2009 Goal Metric More Information
Take a leadership role in U.S. health care reform policy debates Establish Stakeholder Advisory Board to get input on health care reform and facilitate broader dialogue Access to Medicines
Assist in bridging the current gap in prescription coverage for Americans who have recently lost coverage due to unemployment Provide eligible individuals with free Pfizer medicines for up to a year or until they become re-insured Access to Medicines